Changes in urinary albumin as a surrogate for kidney disease progression in people with type 2 diabetes.
Albuminuria
Diabetic kidney disease
Diabetic nephropathy
eGFR
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
received:
18
10
2022
accepted:
07
02
2023
medline:
18
4
2023
pubmed:
26
2
2023
entrez:
25
2
2023
Statut:
ppublish
Résumé
It remains unclear whether urinary albumin changes can predict subsequent kidney disease progression in people with diabetes. This retrospective cohort study included 4570 Japanese adults with type 2 diabetes (T2D). The exposure was changes in urinary albumin-to-creatinine ratio (UACR) over 3 years, categorized into three categories: ≤ - 30%, minor change, or ≥ 30%. During the exposure period, eGFR decline was also examined and categorized into two categories: < 30% or ≥ 30% decline. The primary outcome was the composite of eGFR halving or initiation of kidney replacement therapy (KRT). The secondary outcome was the initiation of KRT. In the spline model, the hazard ratio for the primary outcome increased linearly on the log UACR changes can be a useful surrogate for kidney disease progression in people with T2D. However, when setting a decrease in UACR as the surrogate, it may be necessary to simultaneously evaluate kidney function decline.
Sections du résumé
BACKGROUND
BACKGROUND
It remains unclear whether urinary albumin changes can predict subsequent kidney disease progression in people with diabetes.
METHODS
METHODS
This retrospective cohort study included 4570 Japanese adults with type 2 diabetes (T2D). The exposure was changes in urinary albumin-to-creatinine ratio (UACR) over 3 years, categorized into three categories: ≤ - 30%, minor change, or ≥ 30%. During the exposure period, eGFR decline was also examined and categorized into two categories: < 30% or ≥ 30% decline. The primary outcome was the composite of eGFR halving or initiation of kidney replacement therapy (KRT). The secondary outcome was the initiation of KRT.
RESULTS
RESULTS
In the spline model, the hazard ratio for the primary outcome increased linearly on the log
CONCLUSIONS
CONCLUSIONS
UACR changes can be a useful surrogate for kidney disease progression in people with T2D. However, when setting a decrease in UACR as the surrogate, it may be necessary to simultaneously evaluate kidney function decline.
Identifiants
pubmed: 36840900
doi: 10.1007/s10157-023-02328-y
pii: 10.1007/s10157-023-02328-y
doi:
Substances chimiques
Albumins
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
465-472Informations de copyright
© 2023. The Author(s), under exclusive licence to The Japanese Society of Nephrology.
Références
Fox CS, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662–73.
doi: 10.1016/S0140-6736(12)61350-6
pubmed: 23013602
pmcid: 3771350
Afkarian M, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988–2014. JAMA. 2016;316:602–10.
doi: 10.1001/jama.2016.10924
pubmed: 27532915
pmcid: 5444809
GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–33.
doi: 10.1016/S0140-6736(20)30045-3
American Diabetes Association Professional Practice Committee. 11 Chronic kidney disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S175–84.
doi: 10.2337/dc22-S011
Coresh J, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–31.
doi: 10.1001/jama.2014.6634
pubmed: 24892770
pmcid: 4172342
Levey AS, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64:821–35.
doi: 10.1053/j.ajkd.2014.07.030
pubmed: 25441437
Levey AS, et al. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the national kidney foundation in collaboration With the US food and drug administration and european medicines agency. Am J Kidney Dis. 2020;75:84–104.
doi: 10.1053/j.ajkd.2019.06.009
pubmed: 31473020
Coresh J, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7:115–27.
doi: 10.1016/S2213-8587(18)30313-9
pubmed: 30635225
pmcid: 6379893
Ohkuma T, et al. Combination of changes in estimated GFR and albuminuria and the risk of major clinical outcomes. Clin J Am Soc Nephrol. 2019;14:862–72.
doi: 10.2215/CJN.13391118
pubmed: 31160317
pmcid: 6556720
Oshima M, et al. Combined changes in albuminuria and kidney function and subsequent risk for kidney failure in type 2 diabetes. BMJ Open Diabetes Res Care. 2021;9: e002311.
doi: 10.1136/bmjdrc-2021-002311
pubmed: 34193460
pmcid: 8246293
Matsuo S, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
doi: 10.1053/j.ajkd.2008.12.034
pubmed: 19339088
Waijer SW, et al. Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the EMPA-REG OUTCOME Trial. J Am Heart Assoc. 2020;9: e016976.
doi: 10.1161/JAHA.120.016976
pubmed: 32893717
pmcid: 7727012
Oshima M, et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE Trial. J Am Soc Nephrol. 2020;31:2925–36.
doi: 10.1681/ASN.2020050723
pubmed: 32998938
pmcid: 7790219
Neuen BL, et al. Changes in GFR and albuminuria in routine clinical practice and the risk of kidney disease progression. Am J Kidney Dis. 2021;78:350–60.
doi: 10.1053/j.ajkd.2021.02.335
pubmed: 33895181
Keogh RH, et al. STRATOS guidance document on measurement error and misclassification of variables in observational epidemiology: part 1-Basic theory and simple methods of adjustment. Stat Med. 2020;39:2197–231.
doi: 10.1002/sim.8532
pubmed: 32246539
pmcid: 7450672
Inker LA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63:713–35.
doi: 10.1053/j.ajkd.2014.01.416
pubmed: 24647050
Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO. Clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;2020(98):S1–115.
Levin A, et al. Summary of KDIGO 2012 CKD guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2013;85:49–61.
doi: 10.1038/ki.2013.444
pubmed: 24284513
Greene T, et al. Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation. J Am Soc Nephrol. 2019;30:1756–69.
doi: 10.1681/ASN.2019010009
pubmed: 31292198
pmcid: 6727266
Sumida K, et al. Changes in albuminuria and subsequent risk of incident kidney disease. Clin J Am Soc Nephrol. 2017;12:1941–9.
doi: 10.2215/CJN.02720317
pubmed: 28893924
pmcid: 5718265
Carrero JJ, et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int. 2017;91:244–51.
doi: 10.1016/j.kint.2016.09.037
pubmed: 27927597
Jun M, et al. Changes in albuminuria and the risk of major clinical outcomes in diabetes: results from ADVANCE-ON. Diabetes Care. 2018;41:163–70.
doi: 10.2337/dc17-1467
pubmed: 29079715
Viazzi F, et al. Changes in albuminuria and renal outcome in patients with type 2 diabetes and hypertension: a real-life observational study. J Hypertens. 2018;36:1719–28.
doi: 10.1097/HJH.0000000000001749
pubmed: 29677050
Heerspink HJL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128–39.
doi: 10.1016/S2213-8587(18)30314-0
pubmed: 30635226
Witte EC, et al. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol. 2009;20:436–43.
doi: 10.1681/ASN.2008030292
pubmed: 19092125
pmcid: 2637059
Parving HH, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204–13.
doi: 10.1056/NEJMoa1208799
pubmed: 23121378
Fried LF, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892–903.
doi: 10.1056/NEJMoa1303154
pubmed: 24206457